Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

University of Calgary Joins Trial of LSALT Peptide for Complications in Hospitalized COVID-19 Patients

americanpharmaceuticalreviewJanuary 12, 2021

Tag: University of Calgary , COVID-19 , Arch Biopartners , LSALT peptide

PharmaSources Customer Service